Bliss GVS Pharma Limited faced SEBI enforcement action in 2019 for manipulating stock prices through synchronized trading and creating artificial volumes. The company and its promoters were found guilty of violating PFUTP regulations under SEBI Act. SEBI imposed penalties and trading restrictions on the entity and associated individuals. The case represents typical market manipulation tactics involving coordinated buy-sell orders to inflate share prices artificially, misleading genuine investors about actual market demand.

Bliss GVS Pharma case exemplifies SEBI's enforcement against fraudulent and unfair trade practices (PFUTP) in Indian capital markets. The company orchestrated synchronized trading where multiple entities placed coordinated buy and sell orders to create artificial price movements and volumes, giving false impression of genuine market activity. This manipulation misled retail investors about the stock's actual demand-supply dynamics. SEBI's investigation revealed circular trading patterns, wash sales, and price manipulation schemes typical of pump-and-dump operations. The enforcement action demonstrates SEBI's surveillance capabilities using data analytics to detect unusual trading patterns. Such cases are crucial for maintaining market integrity as they establish deterrent effect against market abuse. The penalties imposed include monetary sanctions, trading bans, and disgorgement of illegal gains. This case reinforces SEBI's role as market watchdog protecting investor interests and ensuring fair price discovery. For SEBI Grade A aspirants, this represents practical application of PFUTP regulations, surveillance mechanisms, and enforcement procedures that form core testing areas in capital market regulation questions.